# SWOG S2213 (NCT06022939)

> Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06022939
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: SWOG Cancer Research Network
- Conditions: AL Amyloidosis
- Interventions: Autologous Hematopoietic Stem Cell Transplantation; Biopsy; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Bortezomib; Computed Tomography; Cyclophosphamide; Daratumumab and Hyaluronidase-fihj; Dexamethasone; Echocardiography; Magnetic Resonance Imaging; Melphalan; Positron Emission Tomography; Stem Cell Isolation; Survey Administration
- Enrollment: 338
- Primary outcome: Major organ deterioration progression-free survival (PFS)

## Indexed commentary on SWOG S2213 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 72

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=swog-s2213-nct06022939

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06022939", "email": "<work email>"}; the inbox owner confirms by the emailed link.